Terms: = Breast cancer AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR AND Treatment
202 results:
1. car-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies.
Niu Z; Wu J; Zhao Q; Zhang J; Zhang P; Yang Y
Front Immunol; 2024; 15():1385571. PubMed ID: 38680498
[TBL] [Abstract] [Full Text] [Related]
2. Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses.
Tapia-Galisteo A; Sánchez-Rodríguez I; Narbona J; Iglesias-Hernández P; Aragón-García S; Jiménez-Reinoso A; Compte M; Khan S; Tsuda T; Chames P; Lacadena J; Álvarez-Vallina L; Sanz L
Oncoimmunology; 2024; 13(1):2338558. PubMed ID: 38623463
[TBL] [Abstract] [Full Text] [Related]
3. B7-H3 Expression in breast cancer and Brain Metastasis.
Joshi V; Beecher K; Lim M; Stacey A; Feng Y; Jat PS; Duijf PHG; Simpson PT; Lakhani SR; McCart Reed AE
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612786
[TBL] [Abstract] [Full Text] [Related]
4. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.
Chowaniec H; Ślubowska A; Mroczek M; Borowczyk M; Braszka M; Dworacki G; Dobosz P; Wichtowski M
Front Immunol; 2024; 15():1375433. PubMed ID: 38576614
[TBL] [Abstract] [Full Text] [Related]
5. Efficacy of the induced pluripotent stem cell derived and engineered CD276-targeted car-NK cells against human esophageal squamous cell carcinoma.
Lin X; Guan T; Xu Y; Li Y; Lin Y; Chen S; Chen Y; Wei X; Li D; Cui Y; Lin Y; Sun P; Guo J; Li C; Gu J; Yang W; Zeng H; Ma C
Front Immunol; 2024; 15():1337489. PubMed ID: 38566988
[TBL] [Abstract] [Full Text] [Related]
6. Engineering a Programmed Death-Ligand 1-Targeting Monobody Via Directed Evolution for SynNotch-Gated Cell Therapy.
Zhu L; Man CW; Harrison RES; Wu Z; Limsakul P; Peng Q; Hashimoto M; Mamaril AP; Xu H; Liu L; Wang Y
ACS Nano; 2024 Mar; 18(11):8531-8545. PubMed ID: 38456901
[TBL] [Abstract] [Full Text] [Related]
7. car-NK cells for cancer immunotherapy: recent advances and future directions.
Li T; Niu M; Zhang W; Qin S; Zhou J; Yi M
Front Immunol; 2024; 15():1361194. PubMed ID: 38404574
[TBL] [Abstract] [Full Text] [Related]
8. Cytotoxicity of fourth-generation anti-Trop2 car-T cells against breast cancer.
Somboonpatarakun C; Phanthaphol N; Suwanchiwasiri K; Ramwarungkura B; Yuti P; Poungvarin N; Thuwajit P; Junking M; Yenchitsomanus PT
Int Immunopharmacol; 2024 Mar; 129():111631. PubMed ID: 38359664
[TBL] [Abstract] [Full Text] [Related]
9. Influence of copper(I) nicotinate complex on the Notch1 signaling pathway in triple negative breast cancer cell lines.
Abdel-Mohsen MA; Badawy AM; Abu-Youssef MA; Yehia MA; Abou Shamaa LD; Mohamed SA
Sci Rep; 2024 Jan; 14(1):2522. PubMed ID: 38291201
[TBL] [Abstract] [Full Text] [Related]
10. New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo.
Jancewicz I; Śmiech M; Winiarska M; Zagozdzon R; Wisniewski P
Cancer Immunol Immunother; 2024 Jan; 73(2):30. PubMed ID: 38279989
[TBL] [Abstract] [Full Text] [Related]
11. Mucin-1-Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid Tumors in Immunocompetent Host.
Zhou R; Wu ST; Yazdanifar M; Williams C; Sanders A; Brouwer C; Maher J; Mukherjee P
J Immunother; 2024 Apr; 47(3):77-88. PubMed ID: 38270462
[TBL] [Abstract] [Full Text] [Related]
12. Novel immunotherapies for breast cancer: Focus on 2023 findings.
Lan HR; Chen M; Yao SY; Chen JX; Jin KT
Int Immunopharmacol; 2024 Feb; 128():111549. PubMed ID: 38266449
[TBL] [Abstract] [Full Text] [Related]
13. The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects.
Ertl C; Ruf T; Mentzer D; Kong M; Kramer R; Bergwelt-Baildon MV; Subklewe M; Tomsitz D; Ascierto PA; Dummer R; Gogas H; Lebbé C; Long GV; McArthur G; Neilan TG; Ribas A; Robert C; Schadendorf D; Zimmer L; Eigentler T; Grabbe S; Forschner A; Kähler KC; Milani V; Pföhler C; Hassel J; Gutzmer R; Loquai C; Routy B; Furness AJS; Blank C; Wolchok JD; French LE; Hauschild A; Heinzerling L
Eur J Cancer; 2024 Mar; 199():113505. PubMed ID: 38262306
[TBL] [Abstract] [Full Text] [Related]
14. Endogenous Signaling Molecule Activating (ESMA) cars: A Novel car Design Showing a Favorable Risk to Potency Ratio for the treatment of Triple Negative breast cancer.
Ebbinghaus M; Wittich K; Bancher B; Lebedeva V; Appelshoffer A; Femel J; Helm MS; Kollet J; Hardt O; Pfeifer R
Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203786
[TBL] [Abstract] [Full Text] [Related]
15. Cocaine regulates antiretroviral therapy CNS access through pregnane-x receptor-mediated drug transporter and metabolizing enzyme modulation at the blood brain barrier.
Colón Ortiz R; Knerler S; Fridman LB; Mercado A; Price AS; Rosado-Franco JJ; Wilkins H; Flores BR; Orsburn BC; Williams DW
Fluids Barriers CNS; 2024 Jan; 21(1):5. PubMed ID: 38200564
[TBL] [Abstract] [Full Text] [Related]
16. Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer.
Shiao SL; Gouin KH; Ing N; Ho A; Basho R; Shah A; Mebane RH; Zitser D; Martinez A; Mevises NY; Ben-Cheikh B; Henson R; Mita M; McAndrew P; Karlan S; Giuliano A; Chung A; Amersi F; Dang C; Richardson H; Shon W; Dadmanesh F; Burnison M; Mirhadi A; Zumsteg ZS; Choi R; Davis M; Lee J; Rollins D; Martin C; Khameneh NH; McArthur H; Knott SRV
Cancer Cell; 2024 Jan; 42(1):70-84.e8. PubMed ID: 38194915
[TBL] [Abstract] [Full Text] [Related]
17. Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies.
Goddard ET; Linde MH; Srivastava S; Klug G; Shabaneh TB; Iannone S; Grzelak CA; Marsh S; Riggio AI; Shor RE; Linde IL; Guerrero M; Veatch JR; Snyder AG; Welm AL; Riddell SR; Ghajar CM
Cancer Cell; 2024 Jan; 42(1):119-134.e12. PubMed ID: 38194912
[TBL] [Abstract] [Full Text] [Related]
18. Pyroptosis and the tumor immune microenvironment: A new battlefield in ovarian cancer treatment.
Wang A; Wang Y; Du C; Yang H; Wang Z; Jin C; Hamblin MR
Biochim Biophys Acta Rev Cancer; 2024 Mar; 1879(2):189058. PubMed ID: 38113952
[TBL] [Abstract] [Full Text] [Related]
19. Harnessing immunotherapy for brain metastases: insights into tumor-brain microenvironment interactions and emerging treatment modalities.
Zhou D; Gong Z; Wu D; Ma C; Hou L; Niu X; Xu T
J Hematol Oncol; 2023 Dec; 16(1):121. PubMed ID: 38104104
[TBL] [Abstract] [Full Text] [Related]
20. The Future of HER2-Targeted treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results.
Nakano K
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069146
[TBL] [Abstract] [Full Text] [Related]
[Next]
